BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34247386)

  • 1. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lacosamide dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Phunpon S; Sathienluckana T; Charoensareerat T; Pattharachayakul S; Rungkitwattanakul D; Srisawat N
    J Intensive Care; 2023 Nov; 11(1):50. PubMed ID: 37946296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
    Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
    J Intensive Care; 2018; 6():61. PubMed ID: 30221005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
    Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
    J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
    Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
    J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01).
    Kalaria SN; Armahizer M; McCarthy P; Badjatia N; Gobburu JV; Gopalakrishnan M
    Clin Transl Sci; 2020 Sep; 13(5):950-959. PubMed ID: 32223067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy.
    Rungkitwattanakul D; Chaijamorn W; Charoensareerat T; Charntrakarn P; Khamkampud O; Rattanaponpasert N; Srisawat N; Pattharachayakul S
    J Crit Care; 2021 Jun; 63():154-160. PubMed ID: 33012583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury.
    Harlan SS; Philpott CD; Keegan SP; Droege ME; Karve AS; Foreman B; Wakefield D; Mueller EW; Sangha K; Ngwenya LB; Courter JD; Desai P; Droege C
    Ann Pharmacother; 2024 Jul; 58(7):705-714. PubMed ID: 37776163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
    Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
    Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
    Li S; Xie F
    Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
    Sember AM; LoFaso ME; Lewis SJ
    J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.